ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者

美股速递
Dec 03, 2025

ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10